Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
- Resource Type
- article
- Source
- Journal for ImmunoTherapy of Cancer, Vol 10, Iss 4 (2022)
- Subject
Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 - Language
- English
- ISSN
- 2051-1426